Author | Year | Sample size | Region | Male/female | Experimental intervention | Compare | Outcome | Follow-up# |
---|---|---|---|---|---|---|---|---|
Massimo Giusti [19] | 2016 | 258 | Italy | 182/76 | Levofloxacin | Prulifloxacin | Clinical cure rates; Relapse of exacerbation; Mortality | 1Y |
Chin Kook Rhee [20] | 2015 | 345 | Korea | 312/33 | Zabofloxacin | Moxifloxacin | Clinical cure rates; Microbiological response; Adverse effects | 36D |
Marjolein Brusse-Keizer [21] | 2014 | 35 | Netherlands | 21/14 | Amoxicillin-clavulanic | Placebo | Clinical cure rates; Relapse of exacerbation | 4Â M |
Sevim Uzun [22] | 2014 | 92 | Netherlands | NA | Azithromycin | Placebo | Adverse effects | 12Â M |
Holl Yoon [23] | 2013 | 137 | Korea | 126/11 | Levofloxacin | Cefuroxime | Clinical cure rates; Microbiological response; Adverse effects | 14D |
F.Blasi [24] | 2013 | 357 | Italy | 222/135 | Prulifloxacin | Levofloxacin | Clinical cure rate; Microbiological response; Adverse effects | 6Â M |
Carl Llor [25] | 2012 | 310 | Spain | 251/59 | Amoxicillin-clavulanic | Placebo | Clinical cure rate; Microbiological response; Adverse effects | 1Y3M |
Robert Wilson [26] | 2012 | 1492 | Multicentre | 833/659 | Moxifloxacin | Amoxicillin-clavulanic | Clinical cure rate; Adverse effects | 8Â W |
Semir Nouira [27] | 2010 | 170 | Tunisia | 155/15 | Trimethoprim-sulfamethoxazole | Ciprofloxacin | Clinical cure rate; Adverse effects; Mortality | 6Â M |
Johannes Daniels [28] | 2010 | 223 | Netherlands | 133/90 | Doxycycline | Placebo | Clinical cure rate; Microbiological response | 30D |
Carl Llor [29] | 2009 | 137 | Spain | 109/28 | Amoxicillin | Amoxicillin-clavulanic | Clinical cure rate; Adverse effects | 30D |
Mara Rubia Andre-Alves [30] | 2007 | 102 | Brazil | 59/43 | Azithromycin | Amoxicillin | Clinical cure rate; Adverse effects | 30D |
Patrick Petitpretz [31] | 2007 | 689 | France | 476/109 | Levofloxacin | cefuroxime | Clinical cure rates; Adverse effects | 6Â M |
H.Lode [32] | 2004 | 511 | Germany | 277/227 | Levofloxacin | Clarithromycin | Clinical cure rate; Microbiological response; Adverse effects | 52Â W |
Ilknur Basyigit [33] | 2004 | 30 | Turkey | 30/0 | Clarithromycin | Placebo | Adverse effect | 14D |
Richard Castaldo [34] | 2003 | 86 | U.S | 38/48 | Dirithromycin | Azithromycin | Clinical cure rate; Adverse effects | 35D |
Semir Nouira [35] | 2001 | 93 | Tunisia | 84/9 | Ofloxacin | Placebo | Clinical cure rate; Adverse effects | 26D |
S.Umut [36] | 1999 | 106 | Turkey | 91/15 | Azithromycin | Ampicillin-sulbactam | Clinical cure rate | 10D |
 |  |  |  |  | Ciprofloxacin | Cefaclor |  |  |
L.Allegra [37] | 1996 | 733 | France | 489/244 | Sparfloxacin | Amoxicillin-clavulanic | Clinical cure rate; Adverse effects | 24D |